Shift in Diabetes Treatment Focus Accelerates Uptake of GLP-1 Medications
Morgan Stanley analysts have observed a significant change in the approach to treating diabetes, with physicians increasingly prioritizing weight management. This shift has led to a faster adoption of GLP-1 medications, which help patients with both weight loss and blood sugar control. The analysts predict that this weight-centric approach will extend beyond diabetes to other health complications, such as heart failure, sleep apnea, and kidney disease, in the next two years.
Novo Nordisk and Eli Lilly Leading the Way
In the GLP-1 category, Novo Nordisk markets semaglutide under the brand names Ozempic and Wegovy for the treatment of type 2 diabetes and obesity, respectively. Eli Lilly has also gained approval for its drug Mounjaro, or tirzepatide, as a type 2 diabetes treatment. Both medications have garnered attention for their ability to lower blood sugar, control food cravings, and aid in weight loss. Furthermore, both companies are developing next-generation products that show great promise in terms of effectiveness, solidifying their dominance in the market.
GLP-1 Medications’ Growing Popularity and Global Expansion
Morgan Stanley reports that GLP-1 medicines now account for nearly 30% of all new diabetes prescriptions in the United States, with approximately 22% of all diabetes prescriptions falling under this category. While the uptake has been slower outside the US, the analysts view this as an opportunity for future growth and estimate global sales, excluding the US, to surpass $70 billion by 2030.
Anticipated Results from Novo’s Select Study
Novo Nordisk’s Select study, set to release its findings in the coming weeks, has attracted significant attention. The five-year study examines the long-term cardiovascular benefits of using Wegovy in obese patients. Positive results from this trial could support the notion that treating obesity with GLP-1 medications leads to improved patient health and potential cost savings within the healthcare system. Insurers are already starting to include coverage for these medications, despite their high costs, with Morgan Stanley noting that reimbursement for obesity medicines has expanded faster than anticipated.
Positive Outlook for GLP-1 Medications and Lilly’s Earnings
Morgan Stanley revised its forecast for the GLP-1 medication market, projecting it to reach $77 billion in 2030, up from the previous estimate of $54 billion. The investment bank also raised its price target for Eli Lilly shares, expecting a 20% increase from Monday’s closing price. Additionally, Wells Fargo predicts that Lilly’s second-quarter revenue will surpass expectations due to strong Mounjaro sales gains. The availability of co-pay assistance coupons and increasing insurance coverage for the drug are contributing factors to this positive outlook.
Overall, the weight-centric approach to diabetes treatment and the growing popularity of GLP-1 medications indicate a transformative shift in healthcare practices, benefiting patients and potentially leading to cost savings in the long run.
